表紙
市場調查報告書

肺炎球菌疫苗:亞太地區的流行病學的預測 (到2028年)

Pneumococcal Vaccines: Epidemiology Forecast in Asia-Pacific Markets to 2028

出版商 GlobalData 商品編碼 932308
出版日期 內容資訊 英文 32 Pages
訂單完成後即時交付
價格
肺炎球菌疫苗:亞太地區的流行病學的預測 (到2028年) Pneumococcal Vaccines: Epidemiology Forecast in Asia-Pacific Markets to 2028
出版日期: 2020年04月01日內容資訊: 英文 32 Pages
簡介

亞太地區的主要國家,已接種肺炎球菌疫苗的兒童人數,從2018年的2008萬7973人,預計2028年增加到2213萬9213人。還有推薦老年人的疫苗接種的國家 (澳洲,日本,韓國,中國 (都市區)) 的實施人數,從2018年的2744萬4336人,2028年預計增加到3900萬2217人。另一方面,侵入性肺炎球菌症 (IPD)的已受診患者的人數,預計從2018年的203萬8634件,2028年減少到188萬0503件。

本報告提供亞太地區的主要5個國家 (澳洲、中國、印度、日本、韓國) 的肺炎球菌疫苗的發病情形與今後預測相關分析,疾病的特徵和目前發病情形,今後10年的發病數量、患病數量的預測值等調查。

第1章 目錄

第2章 肺炎球菌疫苗:概要

第3章 流行病學

  • 疾病的背景情況
  • 風險要素與並存症
  • 全球過去趨勢
    • 兒童/老年人的肺炎球菌疫苗接種率
    • 已受診IPD (侵入性肺炎球菌疾病)的發生率 (每10萬人口病例數)
  • 預測手法
    • 資訊來源
    • 沒使用的資訊來源
    • 預測的前提條件與方法
    • 兒童族群的肺炎球菌疫苗接種率
    • 老年人的肺炎球菌疫苗接種率
    • 已受診IPD的病例數
  • 肺炎球菌疫苗及IPD的流行病學的預測 (2018∼2028年)
    • 接種了肺炎球菌疫苗的兒童族群
    • 接種了肺炎球菌疫苗的老年人族群
    • 已受診IPD的病例數
    • 已受診IPD的病例數:各年齡
  • 討論
    • 流行病學的預測相關考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

目錄
Product Code: GDHCER236-20

Streptococcus pneumoniae (S. pneumoniae) is a bacterial organism that causes a number of diseases, ranging from serious to mild infections. Symptoms depend on the part of the body that is infected, and range from fever, chills, and difficulty breathing to stiff neck and confusion. Transmission of S. pneumoniae primarily occurs through respiratory droplets. The term invasive pneumococcal disease (IPD) refers to more severe infections in which the bacterium is isolated from normally sterile sites. IPD is most common in high-risk groups, such as young children and the elderly, where the immune system is more vulnerable.

GlobalData epidemiologists utilized comprehensive, country-specific pneumococcal vaccination rate data and IPD diagnosed incidence rate data from nationally representative public health surveillance systems and databases to arrive at a meaningful, in-depth epidemiological analysis and forecast. Moreover, GlobalData epidemiologists provide detailed dose- and age-specific pneumococcal vaccination rates that are dependent on the routine immunization requirements of each market.

GlobalData epidemiologists forecast that the pneumococcal vaccinated pediatric population in the 5GM will increase from 20,087,973 children vaccinated in 2018 to 22,139,213 children vaccinated in 2028. In the elderly population in four growth markets (4GM: Australia, Japan, South Korea, and urban China) where vaccination in this age group is recommended, GlobalData epidemiologists forecast an increase from 27,444,336 elderly vaccinated in 2018 to 39,002,217 elderly vaccinated in 2028. In the 5GM in 2018, the average pediatric vaccination rate was approximately 75%, while in the 4GM, the average elderly vaccination rate was approximately 45%. Additionally, GlobalData epidemiologists forecast that the diagnosed incident cases of IPD in the 5GM will decrease from 2,038,634 cases in 2018 to 1,880,503 cases in 2028. In the future, continued efforts should focus on establishing national vaccine initiatives and goals and carrying out a targeted, actionable, and effective country-specific approach to overcome vaccine hesitancy, increase vaccine awareness, and ultimately reduce IPD incidence worldwide.

Scope

  • The Pneumococcal Vaccines Epidemiology report provide an overview of the risk factors and global trends of pneumococcal vaccines in the five growth markets (5GM: Australia, India, Japan, South Korea, and urban China).
  • This report also includes a 10-year epidemiological forecast for the vaccinated pneumococcal population segmented by age (pediatric and elderly), and diagnosed incident cases of IPD segmented by age (0-4 years, 5-9 years, 10-19 years, and by 10-year age groups up to 80 years and older). Pneumococcal vaccine dosing and age groups included within the forecast were dependent on the routine immunization requirements in each market and the availability of vaccination data. In addition, the epidemiology model corresponding to this report provides IPD diagnosed incident cases segmented into the top ten most common IPD serotypes by age (pediatric and elderly).
  • The Pneumococcal Vaccines epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 5GM.

Reasons to Buy

  • The Pneumococcal Vaccines Epidemiology series will allow you to:
  • Develop business strategies by understanding the trends shaping and driving the global pneumococcal vaccines market.
  • Quantify patient populations in the global pneumococcal vaccines market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups that present the best opportunities for pneumococcal vaccine therapeutics in each of the markets covered.
  • Understand magnitude of the pneumococcal vaccines population by dose and age.

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Pneumococcal Vaccines: Executive Summary

  • 2.1 Related Reports
  • 2.2 Upcoming Reports

3 Epidemiology

  • 3.1 Disease Background
  • 3.2 Risk Factors and Comorbidities
  • 3.3 Global and Historical Trends
    • 3.3.1 Pediatric and Elderly Pneumococcal Vaccination Rates
    • 3.3.2 Diagnosed Incidence of Invasive Pneumococcal Disease (Cases per 100,000 Population)
  • 3.4 Forecast Methodology
    • 3.4.1 Sources
    • 3.4.2 Sources Not Used
    • 3.4.3 Forecast Assumptions and Methods
    • 3.4.4 Pneumococcal Vaccination Rates in the Pediatric Population
    • 3.4.5 Pneumococcal Vaccination Rates in the Elderly Population
    • 3.4.6 Diagnosed Incident Cases of Invasive Pneumococcal Disease
  • 3.5 Epidemiological Forecast for Pneumococcal Vaccines and Invasive Pneumococcal Disease (2018-2028)
    • 3.5.1 Pneumococcal Vaccinated Pediatric Population
    • 3.5.2 Pneumococcal Vaccinated Elderly Population
    • 3.5.3 Diagnosed Incident Cases of IPD
    • 3.5.4 Age-Specific Diagnosed Incident Cases of IPD
  • 3.6 Discussion
    • 3.6.1 Epidemiological Forecast Insight
    • 3.6.2 Limitations of Analysis
    • 3.6.3 Strengths of Analysis

4 Appendix

  • 4.1 Bibliography
  • 4.2 About the Authors
    • 4.2.1 Epidemiologist
    • 4.2.2 Reviewers
    • 4.2.3 Global Director of Therapy Analysis and Epidemiology
    • 4.2.4 Global Head and EVP of Healthcare Operations and Strategy
  • 4.3 About GlobalData
  • 4.4 Contact Us
  • 4.5 Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for Invasive Pneumococcal Disease
  • Table 2: Pediatric Pneumococcal Vaccination Rate Trends (%)
  • Table 3: Elderly Pneumococcal Vaccination Rate Trends (%)

List of Figures

  • Figure 1: 5GM, Pneumococcal Vaccinated Pediatric Population, Both Sexes, 2018 and 2028
  • Figure 2: 4GM, Pneumococcal Vaccinated Elderly Population, Both Sexes, 2018 and 2028
  • Figure 3: 4GM, Diagnosed Incidence of IPD, Both Sexes, All Ages, 2008-2028
  • Figure 4: India, Diagnosed Incidence of IPD, Both Sexes, All Ages, 2008-2028
  • Figure 5: 5GM, Sources Used for the Pneumococcal Vaccinated Pediatric Population
  • Figure 6: 4GM, Sources Used for the Pneumococcal Vaccinated Elderly Population
  • Figure 7: 5GM, Sources Used for the Diagnosed Incident Cases of IPD
  • Figure 8: 5GM, Pneumococcal Vaccinated Pediatric Population, Both Sexes, 2018
  • Figure 9: 4GM, Pneumococcal Vaccinated Elderly Population, Both Sexes, 2018
  • Figure 10: 5GM, Diagnosed Incident Cases of IPD, Both Sexes, All Ages, 2018
  • Figure 11: Australia, Japan, and South Korea Age-Specific Diagnosed Incident Cases of IPD, Men and Women, N, 2018
  • Figure 12: India, Age-Specific Diagnosed Incident Cases of IPD, Men and Women, N, 2018
  • Figure 13: Urban China, Age-Specific Diagnosed Incident Cases of IPD, Men and Women, N, 2018